Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomedical Research | 4 | 2023 | 371 | 1.610 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 628 | 0.970 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2020 | 58 | 0.620 |
Why?
|
| Myopia | 8 | 2005 | 26 | 0.570 |
Why?
|
| Georgia | 6 | 2023 | 155 | 0.440 |
Why?
|
| Humans | 53 | 2023 | 34853 | 0.440 |
Why?
|
| Female | 38 | 2023 | 19873 | 0.410 |
Why?
|
| Eyeglasses | 7 | 2005 | 21 | 0.400 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2003 | 75 | 0.400 |
Why?
|
| Visual Acuity | 8 | 2015 | 98 | 0.360 |
Why?
|
| Male | 35 | 2023 | 18870 | 0.350 |
Why?
|
| Resilience, Psychological | 2 | 2020 | 61 | 0.340 |
Why?
|
| Residence Characteristics | 3 | 2021 | 301 | 0.340 |
Why?
|
| Adult | 19 | 2023 | 11034 | 0.330 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2008 | 38 | 0.320 |
Why?
|
| Mentors | 3 | 2023 | 111 | 0.320 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 219 | 0.300 |
Why?
|
| Patient Compliance | 1 | 2008 | 202 | 0.290 |
Why?
|
| Middle Aged | 18 | 2023 | 9642 | 0.290 |
Why?
|
| Aged | 14 | 2023 | 6448 | 0.260 |
Why?
|
| Receptors, KIR | 2 | 2015 | 5 | 0.260 |
Why?
|
| Thyroidectomy | 2 | 2014 | 6 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2020 | 727 | 0.250 |
Why?
|
| Glucocorticoids | 2 | 2015 | 80 | 0.250 |
Why?
|
| Killer Cells, Natural | 2 | 2015 | 86 | 0.250 |
Why?
|
| Health Status Disparities | 2 | 2020 | 583 | 0.250 |
Why?
|
| Disease Progression | 9 | 2008 | 580 | 0.250 |
Why?
|
| Child | 15 | 2020 | 2875 | 0.250 |
Why?
|
| Intraocular Pressure | 4 | 2003 | 121 | 0.240 |
Why?
|
| Adolescent | 9 | 2023 | 5035 | 0.240 |
Why?
|
| Vision Tests | 1 | 2003 | 4 | 0.240 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 2333 | 0.240 |
Why?
|
| Haplotypes | 2 | 2020 | 152 | 0.210 |
Why?
|
| Body Mass Index | 4 | 2021 | 775 | 0.210 |
Why?
|
| Tropicamide | 1 | 2001 | 1 | 0.210 |
Why?
|
| Mydriatics | 1 | 2001 | 5 | 0.210 |
Why?
|
| Pupil | 1 | 2001 | 9 | 0.210 |
Why?
|
| Diploidy | 2 | 2020 | 6 | 0.200 |
Why?
|
| Double-Blind Method | 7 | 2014 | 269 | 0.190 |
Why?
|
| United States | 4 | 2023 | 3894 | 0.190 |
Why?
|
| Young Adult | 5 | 2023 | 4012 | 0.190 |
Why?
|
| Lactobacillus acidophilus | 2 | 2010 | 3 | 0.180 |
Why?
|
| Urban Health | 1 | 2020 | 86 | 0.180 |
Why?
|
| Risk Factors | 9 | 2021 | 3414 | 0.180 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 121 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 528 | 0.180 |
Why?
|
| Probiotics | 2 | 2010 | 25 | 0.180 |
Why?
|
| Convergence, Ocular | 2 | 1999 | 3 | 0.170 |
Why?
|
| Betaxolol | 3 | 2003 | 3 | 0.170 |
Why?
|
| Trabeculectomy | 3 | 2003 | 28 | 0.170 |
Why?
|
| Accommodation, Ocular | 5 | 2004 | 5 | 0.170 |
Why?
|
| Awareness | 1 | 2018 | 59 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2019 | 136 | 0.160 |
Why?
|
| Intention | 1 | 2018 | 84 | 0.160 |
Why?
|
| Medicare | 1 | 2019 | 188 | 0.160 |
Why?
|
| Registries | 2 | 2019 | 330 | 0.160 |
Why?
|
| Parathyroid Hormone | 2 | 2014 | 36 | 0.160 |
Why?
|
| Mortality | 1 | 2019 | 150 | 0.160 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 132 | 0.160 |
Why?
|
| Social Class | 1 | 2019 | 228 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2019 | 311 | 0.140 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 136 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2003 | 50 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 446 | 0.140 |
Why?
|
| Macular Edema | 1 | 2015 | 4 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 964 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2015 | 43 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2015 | 1349 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 56 | 0.130 |
Why?
|
| Lipids | 1 | 2016 | 222 | 0.130 |
Why?
|
| Hypoparathyroidism | 1 | 2014 | 1 | 0.130 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 23 | 0.130 |
Why?
|
| Hydrocephalus | 1 | 2014 | 16 | 0.130 |
Why?
|
| Granisetron | 1 | 2014 | 1 | 0.130 |
Why?
|
| Hypocalcemia | 1 | 2014 | 3 | 0.130 |
Why?
|
| Antiemetics | 1 | 2014 | 7 | 0.130 |
Why?
|
| Vomiting | 1 | 2014 | 13 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 65 | 0.130 |
Why?
|
| HIV Infections | 1 | 2008 | 2207 | 0.130 |
Why?
|
| Gastroenteritis | 1 | 2014 | 17 | 0.130 |
Why?
|
| Prednisolone | 1 | 2014 | 13 | 0.120 |
Why?
|
| Budesonide | 1 | 2014 | 5 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 316 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 24 | 0.120 |
Why?
|
| Eye | 2 | 2005 | 68 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2019 | 1353 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 15 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 3 | 0.120 |
Why?
|
| Prognosis | 5 | 2020 | 707 | 0.120 |
Why?
|
| Sexual Behavior | 1 | 2018 | 587 | 0.110 |
Why?
|
| Saudi Arabia | 3 | 2020 | 6 | 0.110 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 103 | 0.110 |
Why?
|
| Visual Fields | 1 | 2003 | 72 | 0.110 |
Why?
|
| Parents | 1 | 2016 | 288 | 0.110 |
Why?
|
| Refraction, Ocular | 5 | 2005 | 28 | 0.110 |
Why?
|
| Vision Disorders | 1 | 2003 | 59 | 0.110 |
Why?
|
| Sex Factors | 5 | 2014 | 859 | 0.110 |
Why?
|
| Vitamin D | 1 | 2014 | 176 | 0.110 |
Why?
|
| Aging | 1 | 2016 | 639 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1056 | 0.100 |
Why?
|
| Hunger | 1 | 2011 | 7 | 0.100 |
Why?
|
| Dietary Fiber | 1 | 2011 | 42 | 0.100 |
Why?
|
| Calcium | 1 | 2014 | 445 | 0.100 |
Why?
|
| Gene Expression | 1 | 2014 | 639 | 0.100 |
Why?
|
| Vitreous Body | 2 | 2015 | 11 | 0.100 |
Why?
|
| Strabismus | 2 | 2004 | 17 | 0.100 |
Why?
|
| Energy Intake | 1 | 2011 | 160 | 0.090 |
Why?
|
| Body Composition | 1 | 2011 | 146 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 7 | 0.090 |
Why?
|
| Asthma | 1 | 2014 | 363 | 0.090 |
Why?
|
| Exotropia | 1 | 1999 | 4 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2016 | 1318 | 0.090 |
Why?
|
| Bifidobacterium | 1 | 2009 | 3 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2010 | 355 | 0.090 |
Why?
|
| Common Cold | 1 | 2009 | 5 | 0.090 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 1999 | 6 | 0.090 |
Why?
|
| Diarrhea | 1 | 2010 | 84 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2011 | 196 | 0.090 |
Why?
|
| Body Weight | 1 | 2011 | 404 | 0.090 |
Why?
|
| Overweight | 1 | 2011 | 233 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 1998 | 3 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2009 | 79 | 0.080 |
Why?
|
| Optometry | 1 | 1998 | 5 | 0.080 |
Why?
|
| Prevalence | 3 | 2020 | 1425 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2008 | 111 | 0.080 |
Why?
|
| Ophthalmic Solutions | 2 | 2003 | 18 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 178 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2016 | 1961 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2021 | 613 | 0.080 |
Why?
|
| Age Factors | 3 | 2009 | 1007 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 608 | 0.070 |
Why?
|
| Health Care Costs | 1 | 1996 | 69 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 1994 | 10 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2015 | 50 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 217 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 1994 | 11 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 1995 | 73 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 2561 | 0.060 |
Why?
|
| Anterior Chamber | 1 | 2004 | 11 | 0.060 |
Why?
|
| Lens, Crystalline | 1 | 2004 | 14 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1993 | 15 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 901 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 424 | 0.060 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 86 | 0.060 |
Why?
|
| Laser Therapy | 2 | 2003 | 30 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 423 | 0.060 |
Why?
|
| Capacity Building | 1 | 2023 | 78 | 0.050 |
Why?
|
| American Heart Association | 1 | 2021 | 17 | 0.050 |
Why?
|
| Eye Color | 1 | 2001 | 3 | 0.050 |
Why?
|
| Censuses | 1 | 2021 | 24 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 15 | 0.050 |
Why?
|
| Adenosine | 1 | 2020 | 54 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 1426 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2020 | 61 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2021 | 333 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 61 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 124 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 537 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 288 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 292 | 0.040 |
Why?
|
| Physicians | 1 | 2019 | 148 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 356 | 0.040 |
Why?
|
| Florida | 1 | 2018 | 358 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 63 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 87 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 524 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1003 | 0.040 |
Why?
|
| Logistic Models | 1 | 2019 | 894 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 2015 | 11 | 0.030 |
Why?
|
| Health Behavior | 1 | 2020 | 491 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 58 | 0.030 |
Why?
|
| Drug Implants | 1 | 2015 | 19 | 0.030 |
Why?
|
| Universities | 1 | 2018 | 363 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 42 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 102 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 1993 | 392 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 8 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 26 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 165 | 0.030 |
Why?
|
| Thyroid Function Tests | 1 | 2014 | 3 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 157 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2014 | 25 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2014 | 27 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2014 | 17 | 0.030 |
Why?
|
| Arabs | 1 | 2014 | 13 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 3 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1993 | 7 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2014 | 92 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 141 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 212 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 155 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 790 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 841 | 0.030 |
Why?
|
| Survival Analysis | 2 | 1995 | 322 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 641 | 0.030 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1993 | 3 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 114 | 0.030 |
Why?
|
| Lectins | 1 | 1993 | 20 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 94 | 0.030 |
Why?
|
| Sarcoma | 1 | 1993 | 9 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 284 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 1422 | 0.030 |
Why?
|
| Lactones | 1 | 1993 | 20 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1993 | 18 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2014 | 206 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 188 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 528 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 142 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 70 | 0.030 |
Why?
|
| Carcinoma | 1 | 2013 | 94 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2011 | 55 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 1014 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 284 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 38 | 0.020 |
Why?
|
| Chicago | 1 | 1999 | 24 | 0.020 |
Why?
|
| Philadelphia | 1 | 1999 | 15 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 1681 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1996 | 429 | 0.020 |
Why?
|
| Absenteeism | 1 | 2009 | 10 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 29 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 213 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 465 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 592 | 0.020 |
Why?
|
| New York | 1 | 1998 | 69 | 0.020 |
Why?
|
| California | 1 | 1999 | 436 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 517 | 0.020 |
Why?
|
| Urban Population | 1 | 1999 | 318 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 984 | 0.020 |
Why?
|
| Relative Value Scales | 1 | 1996 | 1 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 23 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1996 | 269 | 0.020 |
Why?
|
| Incidence | 1 | 1998 | 882 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 36 | 0.020 |
Why?
|
| Work | 1 | 2004 | 6 | 0.020 |
Why?
|
| Reading | 1 | 2004 | 12 | 0.020 |
Why?
|
| Cisplatin | 1 | 1995 | 70 | 0.020 |
Why?
|
| Lomustine | 1 | 1994 | 1 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1994 | 6 | 0.020 |
Why?
|
| Prednisone | 1 | 1994 | 26 | 0.020 |
Why?
|
| Bleomycin | 1 | 1994 | 18 | 0.020 |
Why?
|
| Biometry | 1 | 2004 | 13 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1994 | 48 | 0.020 |
Why?
|
| Recurrence | 1 | 1994 | 125 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 233 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 80 | 0.010 |
Why?
|
| Anthropometry | 1 | 2004 | 91 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2004 | 115 | 0.010 |
Why?
|
| Prescriptions | 1 | 2003 | 17 | 0.010 |
Why?
|
| Cornea | 1 | 2002 | 55 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 223 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 212 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2001 | 55 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1993 | 20 | 0.010 |
Why?
|
| Pepsin A | 1 | 1993 | 3 | 0.010 |
Why?
|
| Bryostatins | 1 | 1993 | 2 | 0.010 |
Why?
|
| Pronase | 1 | 1993 | 4 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1993 | 5 | 0.010 |
Why?
|
| Ploidies | 1 | 1993 | 5 | 0.010 |
Why?
|
| Macrolides | 1 | 1993 | 11 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 12 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1993 | 19 | 0.010 |
Why?
|
| Trypsin | 1 | 1993 | 39 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 39 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 53 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1993 | 33 | 0.010 |
Why?
|
| Cell Count | 1 | 1993 | 129 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1993 | 116 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1993 | 110 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1993 | 423 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 480 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 562 | 0.010 |
Why?
|